OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Subramanian on the IMpower131 Trial in Squamous NSCLC

March 27th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses the IMpower131 trial in advanced squamous non–small cell lung cancer (NSCLC).

Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer

March 26th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.

Dr. Higano on Role of PARP Inhibitors in Prostate Cancer

March 26th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the role of PARP inhibitors in prostate cancer.

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

March 26th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

Dr. Hunt on Treating Local Regional Recurrence in Breast Cancer

March 26th 2019

Kelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.

Dr. Ferguson on a Population-Based Study of Women Undergoing Radical Hysterectomy

March 26th 2019

Sarah Ferguson, MD, FRCSC, associate professor of gynecologic oncology, University of Toronto, Princess Margaret Cancer Centre, discusses a population-based study of women with cervical cancer undergoing radical hysterectomy.

Dr. Bardia on Sacituzumab Govitecan in TNBC

March 26th 2019

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the potential of sacituzumab govitecan in patients with triple-negative breast cancer (TNBC).

Dr. Perez-Soler on Improved Outlook for Patients With Lung Cancer

March 26th 2019

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the improved outlook for patients with lung cancer.

Dr. Socinski on Mechanisms of Resistance in Lung Cancer

March 26th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.

Dr. Quinn on Targetable Molecular Pathways in RCC

March 26th 2019

David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.

Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

March 22nd 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Sznol on Unanswered Questions With Immunotherapy in RCC

March 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Slovin Discusses History of Immunotherapy in Prostate Cancer

March 22nd 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the history of immunotherapy in the treatment of patients with prostate cancer.

Dr. Saettele on the Benefits of Using Bronchoscopies in NSCLC

March 22nd 2019

Timothy Saettele, MD, interventional pulmonologist at Saint Luke’s Hospital, discusses the benefits of using bronchoscopies in patients with non–small cell lung cancer (NSCLC).

Dr. Oaknin on the GARNET Study in Endometrial Cancer

March 22nd 2019

Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the phase I/II GARNET trial in patients with endometrial cancer.

Dr. Mehta on Immunotherapy in Gastric/GEJ Cancer

March 22nd 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist at Moffitt Cancer Center, discusses the use of immunotherapy in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Mahipal on Treatment of Newly Diagnosed mCRC

March 22nd 2019

Amit Mahipal, MBBS, professor of medicine, Mayo Clinic, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

Dr. Bochner on Molecular Profiling in Bladder Cancer

March 22nd 2019

Bernard H. Bochner, MD, FACS, chair of surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of molecular profiling in the treatment of patients with bladder cancer.

Dr. Gomella Discusses Role of BRCA1/2 in Prostate Cancer

March 22nd 2019

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of BRCA1/2 in patients with prostate cancer.

Dr. Davids on Frontline Challenges in CLL

March 21st 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.